Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 211, Issue 4, Pages 590-599Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiu481
Keywords
dengue virus; neutralizing antibody; inapparent dengue; dengue fever; Sri Lanka
Categories
Funding
- Pediatric Dengue Vaccine Initiative [23197]
- National Institutes of Health [T32AI007419, 5R25GM055336]
Ask authors/readers for more resources
Dengue viruses (DENVs) are mosquito-borne flaviviruses that infect humans. The clinical presentation of DENV infection ranges from inapparent infection to dengue hemorrhagic fever and dengue shock syndrome. We analyzed samples from a pediatric dengue cohort study in Sri Lanka to explore whether antibody responses differentiated clinically apparent infections from clinically inapparent infections. In DENV-naive individuals exposed to primary DENV infections, we observed no difference in the quantity or quality of acquired antibodies between inapparent and apparent infections. Children who experienced primary infections had broad, serotype-cross-neutralizing antibody responses that narrowed in breadth to a single serotype over a 12-month period after infection. In DENV immune children who were experiencing a repeat infection, we observed a strong association between preexisting neutralizing antibodies and clinical outcome. Notably, children with preexisting monospecific neutralizing antibody responses were more likely to develop fever than children with cross-neutralizing responses. Preexisting DENV neutralizing antibodies are correlated with protection from dengue disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available